Immunome IMNM 深 沪
已收盘 10-09 16:00:00 美东时间
19.55
+0.240
+1.24%
华盛通- 最 高19.72
- 今 开19.05
- 成交量 99.82万股
- 最 低 18.88
- 昨 收 19.31
- 总市值 23.07亿
- 52周最高 30.06
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 14.64
- 委 比 61.19%
- 总股本 1.18亿
- 历史最高 63.78
- 量 比 0.62
- 振 幅 4.35%
- 历史最低 2.09
- 每 手 1
- 风险率 3.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a pote...
09-30 19:46
美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32
Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.
09-21 21:50
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
09-10 21:33
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of ServiceTitan Inc (NASDAQ:TTAN) fell sharply in pre-market trading after the company reported second-quarter financial results and issued third-quarter sales guidance with its midpoint below e...
09-09 20:02
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.
08-13 00:09
Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per share from the same period last year.
08-12 04:34
